Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)
Durect Analyst Ratings
Durect Analyst Ratings
Durect (DRRX) Gets a Buy From Oppenheimer
Durect Analyst Ratings
Durect Analyst Ratings
Analysts Offer Insights on Healthcare Companies: NexGel Inc (NXGL), Taysha Gene Therapies (TSHA) and Durect (DRRX)
Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Spero Therapeutics (SPRO) and EFFECTOR Therapeutics (EFTR)
Durect Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Durect (DRRX) and Praxis Precision Medicines (PRAX)
HC Wainwright Downgrades DURECT to Neutral, Removes Price Target
Durect Analyst Ratings
Durect (DRRX) Was Downgraded to a Hold Rating at H.C. Wainwright
H.C. Wainwright Reaffirms Their Buy Rating on Durect (DRRX)
Analysts Offer Insights on Healthcare Companies: Durect (DRRX) and Cytokinetics (CYTK)
Cantor Fitzgerald Adjusts Price Target on Durect to $41 From $44, Keeps Overweight Rating
HC Wainwright & Co. Maintains Buy on Durect, Lowers Price Target to $27
Durect Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Pfizer (PFE) and BioVie (BIVI)
Analyst Ratings for Durect